International Cannabis Weekly
Prohibition Partners
Home / Cannabis Markets / Sweden
Sweden flag

Is cannabis legal in Sweden?

Medical cannabis is legal in Sweden and adult-use is illegal. Below: a free market overview, with the full sizing, regulation and trade data available from PP.

Medical: LegalAdult-use: Illegal
Compare withNorwayFinlandCroatia

Market size

Medical cannabis sales and registered patients in Sweden, 2025 actuals and the 2027 forecast. Forecasts to 2030 are in the Sweden data pack.

Medical sales, EUR

€280.5k2025€442.1k2026€584.1k2027202820292030
Metric202520262027202820292030
Medical sales€280.5k€442.1k€584.1k
Patients459724957

Forecasts to 2030 — sales, patients and the full Sweden series — are in the Sweden data pack, or scoped to your question in a bespoke brief.

See the data pack Request a brief

Source: Prohibition Partners — Global Medical Cannabis Market Review (2026, updated April 2026) & The European Cannabis Report (2025)

Recently in Sweden

From International Cannabis Weekly, our free global briefing.

Latest issue №467
  1. Swedish hemp company boosts production with new fibre processing technology

    №385 · 31 Jan 2025 · Hemp & CBD

  2. UK crown dependencies advance cannabis plans and Swedish cannabis in Switzerland

    №356 · 5 Jul 2024 · Regulation

  3. Proposed Swedish regulatory change restricting hemp components draws criticism

    №235 · 18 Feb 2022 · Regulation

  4. Swedish entrepreneur creates CanCoin cryptocurrency for European cannabis banking

    BusinessCann · №207 · 23 Jul 2021 · Business & Investment

  5. Swedish pharmaceutical company signs licensing agreement with Cannassure

    avanza.se · №181 · 22 Jan 2021 · Business & Investment

  6. Sweden approves STENOCARE and Emerald to provide medical cannabis oil

    stenocare.com · №164 · 11 Sept 2020 · Medical

Medical cannabis — overview

Medical cannabis in the form of oil or flowers is currently only available through a rigorous licence approval process where specialist doctors must submit an application for their patient, reviewed and granted by the Swedish Medical Products Agency.

A prescriber must provide evidence within the application that the unregistered medical cannabis product is beneficial for the well-being of its patient and that other treatment methods have been exhausted.

If a licence is granted, the Swedish Medical Products Agency provides a prescription for three months during which the patient’s effect on the treatment is evaluated, and if the situation is beneficial for the patient, the prescriber may apply for an annual licence. In the last years, the number of medical cannabis licences have been increasing.

In 2024, the Karolinska Institute, in collaboration with Cura Leaf’s Sapphire Clinics, launched a national observational study on the treatment of cannabis-based preparations, collecting data to evaluate the treatment effects of prescribed cannabis-based medicines.